Regulation of smooth muscle cell accumulation in diabetes-accelerated atherosclerosis

Histology and Histopathology

Volumn 17, Issue 4, 2002, Pages 1317-1328

  Askari, B ^a   Renard, C B ^a   Bornfeldt, Karin E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Glucose; Growth factors; Macrovascular complications; Non esterified fatty acids

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE; GROWTH FACTOR; INSULIN; LIPID; RAMIPRIL; TRIACYLGLYCEROL;

ADULT; ARTERY; ATHEROMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CELL AGGREGATION; CELL DEATH; CELL FUNCTION; CELL LOSS; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CLINICAL TRIAL; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIPID STORAGE; MACROPHAGE; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PATHOPHYSIOLOGY; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STROKE; SYMPTOM; TRANSLUMINAL CORONARY ANGIOPLASTY; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ARTERIOSCLEROSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; HUMANS; MUSCLE, SMOOTH;

ANIMALIA;

EID: 0036789780     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., Sukhova G.K. and Libby P. (1998). Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97, 2433-2444.
2. Aoki M., Morishita R., Hayashi S., Jo N., Matsumoto K., Nakamura T., Kaneda Y. and Ogihara T. (2001). Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 44, 1034-1042.
3. Araki N., Higashi T., Mori T., Shibayama R., Kawabe Y., Kodama T., Takahashi K., Shichiri M. and Horiuchi S. (1995). Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur. J. Biochem. 230, 408-415.
4. Askari B., Gerrity R.G., Kramer F. and Bornfeldt K.E. (2001). Free fatty acids potentiate the mitogenic effects of insulin-like growth factor-I in arterial smooth muscle cells. Diabetes 50, 1393 (Abstr).
5. Askari B., Carroll M.A., Capparelli M., Kramer F., Gerrity R.G. and Bornfeldt K.E. (2002). Oleate and linoleate enhance the growth-promoting effects of IGF-I through a phospholipase D-dependent pathwan arterial smooth muscle cells. J. Biol. Chem. (in press).
6. Avena R., Mitchell M.E., Carmody B., Arora S., Neville R.F. and Sidaway A.N. (1999). Insulin-like growth factor-1 receptors mediate infragenicular vascular smooth muscle cell proliferation in response to glucose and insulin not by insulin receptors. Am. J. Surg. 178, 156-161.
7. Babaev V.R., Patel M.B., Semenkovich C.F., Fazio S. and Linton M.F. (2000). Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J. Biol. Chem. 275, 26293-26299.
8. Baynes J.W. and Thorpe S.R. (2000). Glycoxidation and lipoxidation in atherogenesis. Free. Radic. Biol. Med. 28, 1708-1716.
9. Begum N. and Ragolia L. (2000). High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol. Cell. Physiol. 278, C81-C91.
10. Berk B.C. (2001). Vascular smooth muscle growth: autocrine growth mechanisms. Physiol. Rev. 81, 999-1030.
11. Bianchi S., Bigazzi R., Quinones Galvan A., Muscelli E., Baldari G., Pecori N., Ciociaro D., Ferrannini E. and Natali A. (1995). Insulin resistance in microalbuminuric hypertension. Sites and mechanisms. Hypertension 26, 789-795.
12. Bobryshev Y.V., Babaev V.R., Iwasa S., Lord R.S. and Watanabe T. (1999). Atherosclerotic lesions of apolipoprotein E deficient mice contain cells expressing S100 protein. Atherosclerosis 143, 451-454.
13. Bornfeldt K.E., Gidlöf R.A., Wasteson Å., Lake M., Skottner A. and Arnqvist H.J. (1991). Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34, 307-313.
14. Bornfeldt K.E., Arnqvist H.J. and Capron L. (1992). In vivo proliferation of rat vascular smooth muscle in relation to diabetes mellitus insulin-like growth factor I and insulin. Diabetologia 35, 104-108.
15. Bornfeldt K.E., Raines E.W., Nakano T., Graves L.M., Krebs E.G. and Ross R. (1994). Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J. Clin. Invest. 93, 1266-1274.
16. Brand K.A. and Hermfisse U. (1997). Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 11, 388-395.
17. Brownlee M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820.
18. Brunzell J.D. (1995). Lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: The metabolic and molecular basis of inherited disease. 7th ed. Vol. 2. Scriver C.R., Beaudet A.L., Sly W.S. and Valle D. (eds). McGraw Hill, Inc. New York. pp. 1913-1932
19. Chu Y., Faraci F.M., Ooboshi H. and Heistad D.D. (1997). Increase in TUNEL positive cells in aorta from diabetic rats. Endothelium 5, 241-250.
20. Clee S.M., Bissada N., Miao F., Miao L., Marais A.D., Henderson H.E., Steures P., McManus J., McManus B., LeBoeuf R.C., Kastelein J.J. and Hayden M.R. (2000). Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J. Lipid Res. 41, 521-531.
21. Dang C.V. and Semenza G.L. (1999). Oncogenic alterations of metabolism. TIBS. 24, 68-72.
22. Dahlfors G., Chen Y., Gustafsson B. and Arnqvist H.J. (2000). Inhibitory effect of diabetes on proliferation of vascular smooth muscle after balloon injury in rat aorta. Int. J. Exp. Diabetes Res. 1, 101-109.
23. Daugherty A., Manning M.W. and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 105, 1605-1612.
24. DCCT; The Diabetes Control and Complication Trial Research Group. (1993). The effects of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986.
25. Dixon J.L., Stoops J.D., Parker J.L., Laughlin M.H., Weisman G.A. and Sturek M. (1999). Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler. Thromb. Vasc. Biol. 19, 2981-2992.
26. Du X., Jiang Y., Qian W., Lu X. and Walsh J.P. (2001). Fatty acids inhibit growth-factor-induced diacylglycerol kinase α activation in vascular smooth-muscle cells. Biochem. J. 257, 275-282.
27. Erkelend D.W. (1998). Diabetic dyslipidaemia. Eur. Heart J. 19, H27-H30.
28. Faergeman O. (2000). Hypertriglyceridemia and the fibrate trials. Curr. Opin. Lipidol. 11, 609-614.
29. Ferns G.A., Raines E.W., Sprugel K.H., Motani A.S., Reidy M.A. and Ross R. (1991). Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253, 1129-1132.
30. Ferrier T.M. (1967). Comparative study of arterial disease in amputated lower limbs from diabetics and non-diabetics (with special reference to feet arteries). Med. J. Aust. 1, 5-11.
31. Geng Y.J. and Libby P. (1995). Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 β-converting enzyme. Am. J. Pathol. 147, 251-266.
32. Gerrity R.G., Natarajan R., Nadler J.L. and Kimsey T. (2001). Diabetes-induced accelerated atherosclerosis in swine. Diabetes 50, 1654-1665.
33. Glass C.K. and Witztum J.L. (2001). Atherosclerosis. the road ahead. Cell 104, 503-516.
34. Gordon D. and Rekhter M.D. (1997). The growth of human atherosclerosis: Cell proliferation and collagen synthesis. Cardiovasc. Pathol. 6, 103-116.
35. Gouni-Berthold I., Berthold H.K., Seul C., Ko Y., Vetter H. and Sachinidis A. (2001). Effects of authentic and VLDL hydrolysis-derived fatty acids on vascular smooth muscle cell growth. Br. J. Pharmacol. 132, 1725-1734.
36. Hall J.L., Matter C.M., Wang X. and Gibbons G.H. (2000). Hyperglycemia inhibits vascular smooth muscle cell apoptosis through a protein kinase C-dependent pathway. Circ. Res. 87, 574-580.
37. Hamilton J.A. and Kamp F. (1999). How are free fatty acids transported in membranes? Is it by proteins or by free diffusion through the lipids? Diabetes 48, 2255-2269.
38. Hasdai D., Rizza R.A., Grill D.E., Scott C.G., Garratt K.N. and Holmes D.R. Jr. (2001). Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization. Am. Heart J. 141, 117-123.
39. Hattori Y., Suzuki M., Hattori S. and Kasai K. (2002). Vascular smooth muscle cell activation by glycated albumin (amadori adducts). Hypertension 39, 22-28.
40. HOPE study investigators (2000). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259.
41. Huang E.S., Meigs J.B. and Singer D.E. (2001). The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am. J. Med. 111, 633-642.
42. Iino K., Yoshinari M., Yamamoto M., Kaku K., Doi Y., Ichikawa K., Iwase M. and Fujishima M. (1996). Effect of glycated collagen on proliferation of human smooth muscle cells in vitro. Diabetologia 39, 800-806.
43. Inaba T., Ishibashi S., Gotoda T., Kawamura M., Morino N., Nojima Y., Kawakami M., Yazaki Y. and Yamada N. (1996). Enhanced expression of platelet-derived growth factor-β receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. Diabetes 45, 507-512.
44. Indolfi C., Torella D., Cavuto L., Davalli A.M. Coppola C., Esposito G., Carriero M.V., Rapacciuolo A., Di Lorenzo E., Stabile E., Perrino C., Chieffo A., Pardo F. and Chiariello M. (2001). Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats. Circulation 103, 2980-2986.
45. Ivandic B., Castellani L.W., Wang X.P., Qiao J.H., Mehrabian M., Navab M., Fogelman A.M., Grass D.S., Swanson M.E., de Beer M.C., de Beer F. and Lusis A.J. (1999). Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 19, 1284-1290.
46. Jawien A., Bowen-Pope D.F., Lindner V., Schwartz S.M. and Clowes A.W. (1992). Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 89, 507-511.
47. Kasai T., Ohguchi K., Nakashima S., Ito Y., Naganawa T., Kondo N. and Nozawa Y. (1998). Increased activity of oleate-dependent type phospholipase D during actinomycin D-induced apoptosis in Jurkat T cells. J. Immunol. 161, 6469-6474.
48. Keren P., George J., Shaish A., Levkovitz H., Janakovic Z., Afek A., Goldberg I., Kopolovic J., Keren G. and Harats D. (2000). Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. Diabetes 49, 1064-1069.
49. Kim J.H., Kim Y., Lee S.D., Lopez I., Arnold R.S., Lambeth J.D., Suh P.G. and Ryu S.H. (1999). Selective activation of phospholipase D2 by unsaturated fatty acid. FEBS Lett. 454, 42-46.
50. Kirstein M., Brett J., Radoff S., Ogawa S., Stern D. and Vlassara H. (1990). Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. USA. 87, 9010-9014.
51. Kirstein M., Aston C., Hintz R. and Vlassara H. (1992). Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J. Clin. Invest. 90, 439-446.
52. Kislinger T., Tanji N., Wendt T., Qu W., Lu Y., Ferran L.J. Jr, Taguchi A., Olson K., Bucciarelli L., Goova M., Hofmann M.A., Cataldegirmen G., D'Agati V., Pischetsrieder M., Stern D.M. and Schmidt A.M. (2001). Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21, 905-910.
53. Kockx M.M., De Meyer G.R., Buyssens N., Knaapen M.W., Bult H. and Herman A.G. (1998). Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ. Res. 83, 378-387.
54. Kockx M.M. and Herman A.G. (2000). Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res. 45, 736-746.
55. Kornowski R., Mintz G.S., Lansky A.J., Hong M.K., Kent K.M., Pichard A.D., Satler L.F., Popma J.J., Bucher T.A. and Leon M.B. (1998). Paradoxic decreases in atherosclerotic plaque mass in insulin-treated diabetic patients. Am. J. Cardiol. 81, 1298-1304.
56. Kwok C.F., Shih K.C., Hwu C.M. and Ho L.T. (2000). Linoleic acid and oleic acid increase the endothelin-1 binding and action in cultured rat aortic smooth muscle cells. Metabolism 49, 1386-1389.
57. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A. and Schmidt A.M. (1997). Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272, 17810-17814.
58. Lehto S., Rönnemaa T., Pyöräräl K. and Laakso M. (2000). Cardiovascular risk factors clustering with endogenous hyperinsulinemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 43, 148-155.
59. Li Y.M., Mitsuhashi T., Wojciechowicz D., Shimizu N., Li J., Stitt A., He C., Banerjee D. and Vlassara H. (1996). Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. USA. 93, 11047-11052.
60. Lindström T., Eriksson P., Olsson A.G. and Arnqvist H.J. (1994). Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure. Diabetes Care 17, 719-721.
61. Lu G., Morinelli T.A., Meier K.E., Rosenzweig S.A. and Egan B.M. (1996). Oleic acid-induced mitogenic signaling in vascular smooth muscle cells. A role for protein kinase C. Circ. Res. 79, 611-618.
62. Lu G., Meier K.E., Jaffa A.A., Rosenzweig S.A. and Egan B.M. (1998a). Oleic acid and angiotensin II induce a synergistic mitogenic response in vascular smooth muscle cells. Hypertension 31, 978-985.
63. Lu G., Greene E.L., Nagai T. and Egan B.M. (1998b). Reactive oxygen species are critical in the oleic acid-mediated mitogenic signaling pathway in vascular smooth muscle cells. Hypertension 32, 1003-1010.
64. Lu X., Yang X.Y., Howard R.L. and Walsh J.P. (2000). Fatty acids modulate protein kinase C activation in porcine vascular smooth muscle cells independently of their effect on de novo diacylglycerol synthesis. Diabetologia 43, 1136-1144.
65. McCarthy N.J. and Bennett M.R. (2000). The regulation of vascular smooth muscle apoptosis. Cardiovasc. Res. 45, 747-755.
66. McClain D.A., Paterson A.J., Roos M.D., Wei X. and Kudlow J.E. (1992). Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. Proc. Natl. Acad. Sci. USA 89, 8150-8154.
67. Mead J.R., Cryer A. and Ramji D.P. (1999). Lipoprotein lipase, a key role in atherosclerosis? FEBS Lett. 462, 1-6.
68. Merkel M., Velez-Carrasco W., Hudgins L.C. and Breslow J.L. (2001). Compared with saturated fatty acids, dietary monounsaturated fatty acids and carbohydrates increase atherosclerosis and VLDL cholesterol levels in LDL receptor-deficient, but not apolipoprotein E-deficient, mice. Proc. Natl. Acad. Sci. USA 98, 13294-13299.
69. Michaud S.E. and Renier G. (2001). Direct regulatory effect of fatty acids on macrophage lipoprotein lipase: potential role of PPARs. Diabetes 50, 660-666.
70. Mizutani K., Ikeda K. and Yamori Y. (2000). Resveratrol inhibits AGEs-induced proliferation and collagen synthesis activity in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Biochem. Biophys. Res. Commun. 274, 61-67.
71. Moreno P.R., Fallon J.T., Murcia A.M., Leon M.N., Simosa H., Fuster V. and Palacios I.F. (1999). Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. J. Am. Coll. Cardiol. 34, 1045-1049.
72. Morrison A.D., Berwick L., Orci L. and Winegrad A.I. (1976). Morphology and metabolism of an aortic intima-media preparation in which an intact endothelium is preserved. J. Clin. Invest. 57, 650-660.
73. 2 concentration and albumin on respiration and aerobic glycolysis in rabbit aortic intima-media. Biochem Med. 20, 279-283.
74. Natarajan R., Gonzalez N., Xu L. and Nadler J.L. (1992) Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem. Biophys. Res. Commun. 187, 552-560.
75. Natarajan R., Bai W., Lanting L., Gonzalez N. and Nadler J. (1997). Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am. J. Physiol. 273, H2224-H2231.
76. Natarajan R., Reddy M.A., Malik K.U., Fatima S. and Khan B.V. (2001). Signaling mechanisms of nuclear factor-κb-mediated activation of inflammatory genes by 13-hydroperoxyoctadecadienoic acid in cultured vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 21, 1408-1413.
77. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D. and Shaw A. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267, 14998-145004.
78. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I. and Brownlee M. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790.
79. O'Brien K.D., Gordon D., Deeb S., Ferguson M. and Chait A. (1992). Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques. J. Clin. Invest. 89, 1544-1550.
80. Ohgami N., Nagai R., Ikemoto M., Arai H., Kuniyasu A., Horiuchi S. and Nakayama H. (2001). CD36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J. Biol. Chem. 276, 3195-3202.
81. Park L., Raman K.G., Lee K.J., Lu Y., Ferran L.J. Jr., Chow W.S., Stern D. and Schmidt A.M. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Med. 4, 1025-1031.
82. Park S.H., Marso S.P., Zhou Z., Foroudi F., Topol E.J. and Lincoff A.M. (2001). Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation 104, 815-819.
83. Paul R.J., Bauer M. and Pease W. (1979). Vascular smooth muscle: aerobic glycolysis linked to sodium and potassium transport processes. Science 206, 1414-1416.
84. Peiro C., Lafuente N., Matesanz N., Cercas E., Llergo J.L., Vallejo S., Rodriguez-Manas L. and Sanchez-Ferrer C.F. (2001). High glucose induces cell death of cultured human aortic smooth muscle cells through the formation of hydrogen peroxide. Br. J. Pharmacol. 133, 967-974.
85. Pentikäinen M.O., Oksjoki R., Öörni K. and Kovanen P.T. (2002). Lipoprotein lipase in the arterial wall: linking LDL to the arterial extracellular matrix and much more. Arterioscler. Thromb. Vasc. Biol. 22, 211-217.
86. Pinkney J.H., Foyle W.J., Denver A.E., Mohamed-Ali V., McKinlay S. and Yudkin J.S. (1995). The relationship of urinary albumin excretion rate to ambulatory blood pressure and erythrocyte sodium-lithium countertransport in NIDDM. Diabetologia 38, 356-362.
87. Rao G.N., Alexander R.W. and Runge M.S. (1995). Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J. Clin. Invest. 96, 842-847.
88. Reaven G.M. (1988). Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37, 1595-1607.
89. Rekhter M.D., Hicks G.W., Brammer D.W., Hallak H., Kindt E., Chen J., Rosebury W.S., Anderson M.K., Kuipers P.J. and Ryan M.J. (2000). Hypercholesterolemia causes mechanical weakening of rabbit atheroma: local collagen loss as a prerequisite of plaque rupture. Circ. Res. 86, 101-108.
90. Renard C.B. and Bornfeldt K.E. (2001). Human arterial smooth muscle cells rapidly deplete cell culture media of glucose. Diabetologia 44, 1067-1068.
91. Renard C.B., Suzuki L.A. and Bornfeld K.E. (2001). Human arterial smooth muscle cells express RAGE but CML-modified proteins do not induce their proliferation. Diabetes 50, 666 (Abstr).
92. Richieri G.V., Anel A. and Kleinfeld A.M. (1993). Interactions of long-chain fatty acids and albumin: determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry 32, 7574-7580.
93. Ridray S., Ktorza A., Picon L. and Capron L. (1992). In vivo effect of insulin on the acute proliferative response of the rat to injury. Arterioscler. Thromb. 12, 633-638.
94. Robins S.J. (2001). Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am. J. Cardiol. 88, 12 Suppl 1, 19-23.
95. Rong J.X.,Li J., Reis E.D., Choudhury R.P., Dansky H.M., Elmalem V.I., Fallon J.T., Breslow J.L. and Fisher E.A. (2001). Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104, 2447-2452.
96. Rosenfeld M.E., Polinsky P., Virmani R., Kauser K., Rubanyi G. and Schwartz S.M. (2000). Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler. Thromb. Vasc. Biol. 20, 2587-2592.
97. Ross R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809.
98. Ruderman N.B. and Haudenschild C. (1984). Diabetes as an atherogenic factor. Prog. Cardiovasc. Dis. 26, 373-412.
99. Sakakibara F., Hotta N., Koh N. and Sakamoto N. (1993). Effects of high glucose concentrations and epalrestat on sorbitol and myoinositol metabolism in cultured rabbit aortic smooth muscle cells. Diabetes 42, 1594-1600.
100. Sakata N., Meng J. and Takebayashi S. (2000). Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J. Atheroscler. Thromb. 7, 169-176.
101. Sartippour M.R., Lambert A., Laframboise M., St-Jacques P. and Reiner G. (1998). Stimulatory effect of glucose on macrophage lipoprotein lipase expression and production. Diabetes 47, 431-438.
102. Sartippour M.R. and Reiner G. (2000). Upregulation of macrophage lipoprotein lipase in patients with type 2 diabetes: role of peripheral factors. Diabetes 49, 597-602.
103. Satoh H., Togo M., Hara M., Miyata T., Han K., Maekawa H., Ohno M., Hashimoto Y., Kurokawa K. and Watanabe T. (1997). Advanced glycation endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 239, 111-115.
104. Schaub F.J., Han D.K., Liles W.C., Adams L.D., Coats S.A., Ramachandran R.K., Seifert R.A., Schwartz S.M. and Bowen-Pope D.F. (2000). Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nature Med. 6, 790-796.
105. Schiller N.K. and McNamara D.B. (1999). Balloon catheter vascular injury of the alloxan-induced diabetic rabbit: the role of insulin-like growth factor-1. Mol. Cell. Biochem. 202, 159-167.
106. Schmidt A.M. and Stern D.M. (2001). Receptor for AGE (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front. Biosci. 6, D1151-D1160.
107. Schwartz S.M., Virmani R. and Rosenfeld M.E. (2000). The good smooth muscle cells in atherosclerosis. Curr. Atheroscler. Rep. 2, 422-429.
108. Semenkovich C.F. and Heinecke J.W. (1997). The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 46, 327-334.
109. Skøyum R., Eide K., Berg K. and Rofstad E.K. (1997). Energy metabolism in human melanoma cells under hypoxic and acidic conditions in vitro. Br. J. Cancer 76, 421-426.
110. Sowers J.R., Epstein M. and Frohlich E.D. (2001). Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37, 1053-1059.
111. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W. Jr., Rosenfeld M.E., Schwartz C.J., Wagner WD. and Wissler R.W. (1995). A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92, 1355-1374.
112. Steiner G. (2001). Treating lipid abnormalities in patients with type 2 diabetes mellitus. Am. J. Cardiol. 88, 12 Suppl 1, 37-40.
113. Stout R.W. (1996). Hyperinsulinemia and atherosclerosis. Diabetes 45 Suppl 3, S45-S46.
114. Strandness D.E. Jr, Priest R.E. and Gibbons G.E. (1964). Combined clinical and pathological study of diabetic and nondiabetic peripheral artery disease. Diabetes 13, 366-372.
115. Suzuki L.A., Poot M., Gerrity R.G. and Bornfeldt K.E. (2001). Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes 50, 851-860.
116. Tabas I. (2000). Cholesterol and phospholipid metabolism in macrophages. Biochim. Biophys. Acta. 1529, 164-174.
117. Takata K., Horiuchi S., Araki N., Shiga M., Saitoh M. and Morino Y. (1988). Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J. Biol. Chem. 263, 14819-14825.
118. Taskinen M.R. (2001). Pathogenesis of dyslipidemia in type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 109 (Suppl 2) S180-S188.
119. UKPDS Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352, 837-853.
120. Van Eck M., Zimmermann R., Groot P.H., Zechner R. and Van Berkel T.J. (2000). Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, E53-E62.
121. Vamecq J. and Latruffe N. (1999). Medical significance of peroxisome proliferator-activated receptors. Lancet 354, 141-148.
122. Vlassara H. and Palace M.R. (2002). Diabetes and advanced glycation endproducts. J. Intern. Med. 251, 87-101.
123. Watson P.A., Nesterova A., Burant C.F., Klemm D.J. and Reusch J.E. (2001). Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration. J. Biol. Chem. 276, 46142-46150.
124. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M. and Wautier J.L. (2001). Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280, E685-E694.
125. Wendt T., Bucciarelli L., Qu W., Lu Y., Yan S.F., Stern D.M. and Schmidt A.M. (2002). Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr. Atheroscler. Rep. 4, 228-237.
126. Williams B., Gallacher B., Patel H. and Orme C. (1997). Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 46, 1497-1503.
127. +-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J. Clin. Invest. 96, 733-740.
128. Yasunari K., Kohno M., Kohno M., Yokokawa K., Horio T. and Yoshikawa J. (1995). Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. Arterioscler. Thromb. Vasc. Biol. 15, 2207-2212.
129. Yki-Järvinen H. (2001). Management of type 2 diabetes mellitus and cardiovascular risk. Drugs 60, 975-983.
130. Yu H.Y., Inoguchi T., Kakimoto M., Nakashima N., Imamura M., Hashimoto T., Umeda F. and Nawata H. (2001). Saturated non-esterified fatty acids stimulate de novo diacylglycerol synthesis and protein kinase C activity in cultured aortic smooth muscle cells. Diabetologia 44, 614-620.
131. Zimmet P., Alberti K.G. and Shaw J. (2001). Global and societal implications of the diabetes epidemic. Nature 414, 782-787.
132. Zhou Z.M., Marso S.P., Schmidt A.M., Stern D.M., Qu W., Forudi F., Wang K., Lincoff A.M. and Topol E.J. (2001). Blockade of receptor for advanced glycation end-products (RAGE) suppresses neointimal formation in diabetic rat carotid injury model. Circulation 104 (suppl. 2) 1202 (Abstr).